Article

“The drug development pipeline for glioblastoma - a cross sectional assessment of the FDA Orphan Drug Product designation database”

2021-01-04

Abstract excerpt

<h4>Background</h4> Glioblastoma multiforme (GBM) is the most common malignant brain tumor among adult patients and represents an almost universally fatal disease. Novel therapies for GBM are being developed under the orphan drug legislation and the knowledge on the molecular makeup of this disease has been increasing rapidly. However, the clinical outcomes in GBM patients with currently available therapies are st...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 188cedcb-9820-5820-8d8a-c809213d6f3c
DOI: 10.1101/2021.01.01.21249120

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

“The drug development pipeline for glioblastoma - a cross sectional assessment of the FDA Orphan Drug Product designation database”DOI 10.1101/2021.01.01.21249120Read

Characterization of prevalent tyrosine kinase inhibitors and their challenges in glioblastoma treatmentSemantic proximity Read

A Patient-Derived Cell Atlas Informs Precision Targeting of Glioblastoma.Semantic proximity Read

Molecular matched targeted therapies for primary brain tumors-a single center retrospective analysis.Semantic proximity Read

Four decades of glioblastoma targeted therapy: a bibliometric and pharmacological perspective on translational failure and future directionsSemantic proximity Read

Repurposing of CNS accumulating drugs Gemfibrozil and Doxylamine for enhanced sensitization of glioblastoma cells through modulation of autophagySemantic proximity Read

A multistep in silico approach identifies potential glioblastoma drug candidates via inclusive molecular targeting of glioblastoma stem cellsSemantic proximity Read

Indications and pivotal trials of the FDA approved small-molecular kinase inhibitors in cancer therapies with and without biomarker of cancer driver geneSemantic proximity Read

Target-Driven Tissue-Agnostic Drug Approvals; a New Path of Drug DevelopmentSemantic proximity Read

BMS345541 is predicted as a repurposed drug for the treatment of TMZ-resistant Glioblastoma using target gene expression and virtual drug screeningSemantic proximity Read

Drug repurposing using transcriptome sequencing and virtual drug screening in a patient with glioblastoma.Semantic proximity Read

A Decade of Innovation: Medicinal Products with New Active Substances Centrally Authorized Within EU Between 2011 and 2020Semantic proximity Read

Proteasome Inhibitors against Glioblastoma—Overview of Molecular Mechanisms of Cytotoxicity, Progress in Clinical Trials, and Perspective for Use in Personalized MedicineSemantic proximity Read